Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries

Gudu, T.; Etcheto, Adrien; Wit, Maarten de; Heiberg, Turid; Maccarone, Mara; Bălănescu, Andra; Bálint, Péter; Niedermayer, Dora; Cañete, Juan D.; Helliwell, Philip S.; Kalyoncu, Umut; Kiltz, Uta; Otsa, Kati; Veale, Douglas J.; Vlam, Kurt de; Scrivo, Rossana; Stamm, Tanja; Kvien, Tore K; Gossec, Laure

doi:10.1016/j.jbspin.2015.07.017

Cited by 50 publications

(49 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-four domains were identified from the SLR, with 18 measured in addition to the core set (Figure 1). The changes over time are likely related to dissemination of the PsA core set, recognition of the importance of fatigue, productivity and other aspects of life impact for patients (8, 12–14), and availability of outcome measures for domains such as dactylitis (15). …”

Section: Summary Of Research Conducted In Preparation For Omeract 2016mentioning

confidence: 99%

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Orbai

Wit²,

Mease³

et al. 2017

J Rheumatol

Self Cite

105

View full text Add to dashboard Cite

Objectives The current psoriatic arthritis (PsA) Core Domain Set defines core domains to be measured in randomized controlled trials (RCTs) and longitudinal observational studies (LOS) and was published in 2006. At the Outcome Measures in Rheumatology (OMERACT) meeting in 2014, researchers, clinicians and patients unanimously voted for updating the PsA Core Domain Set to include the patient perspective in accordance with OMERACT Filter 2.0. Herein we report the proceedings of the PsA Workshop at the OMERACT meeting in 2016 including studies presented in the plenary, results of breakout group discussions, and final voting and endorsement of the 2016 updated PsA Core Domain Set. Methods We conducted research to develop the updated PsA Core Domain Set. At OMERACT 2016 this work was presented, discussed in breakout groups and the updated PsA core domain set was voted on and endorsed by OMERACT participants. Results The updated PsA Core Domain Set includes: musculoskeletal disease activity, skin disease activity, fatigue, pain, patient global, physical function, health related quality of life and systemic inflammation which are recommended for all RCTs and LOS). Economic cost, emotional well-being, participation and structural damage are important but not required in all RCTs and LOS. Independence, sleep, stiffness and treatment burden on the research agenda. Conclusion The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of available outcome measures for each of the core domains and development of a PsA core outcome measurement set.

show abstract

Section: Summary Of Research Conducted In Preparation For Omeract 2016mentioning

confidence: 99%

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Orbai

Wit²,

Mease³

et al. 2017

J Rheumatol

Self Cite

105

View full text Add to dashboard Cite

show abstract

“…Indeed, the 2016 OMERACT-endorsed PsA core domain set for measurement in PsA clinical trials, which was developed with significant patient input, now includes both fatigue and social participation as more than 70% of patients reported these as important domains to be considered in PsA clinical trials [57]. Although fatigue levels are high in both PsA [58] and AxSpA [59], it can often be hard to manage because of its multifactorial etiology. Studies have indicated that fatigue is mostly associated with disease-related factors, such as disease activity and function, but also with patient-related factors, such as mental health and psychological distress [58][59][60][61][62].…”

Section: Focusing On Patients' Priorities For Treatment Goalsmentioning

confidence: 99%

“…Although fatigue levels are high in both PsA [58] and AxSpA [59], it can often be hard to manage because of its multifactorial etiology. Studies have indicated that fatigue is mostly associated with disease-related factors, such as disease activity and function, but also with patient-related factors, such as mental health and psychological distress [58][59][60][61][62]. To this end, psychological interventions, such as information on Mindfulness-Based Stress Reduction (MBSR), may prove beneficial for the management of fatigue in rheumatic disorders [63].…”

Section: Focusing On Patients' Priorities For Treatment Goalsmentioning

confidence: 99%

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Garrido‐Cumbrera

Hillmann²,

Mahapatra

et al. 2017

Rheumatol Ther

Self Cite

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are both chronic, inflammatory conditions that result in a substantial burden of disease and reduced quality of life for patients. Patient involvement in developing optimal disease management strategies, including defining appropriate goals, therapies, and treatment options, as well as in setting policy priorities and agendas, is key. A working group of patient organization representatives and rheumatologists explored what patients consider to be unmet needs, important treatment gaps, and future priorities in PsA and AxSpA management. Reducing pain and fatigue, and improving physical and social functioning and work productivity were identified as important treatment goals for patients. Although the major treatment target for both PsA and AxSpA is remission, with low/minimal disease activity an alternative target for patients with established or long-standing disease, the meaning of remission from the patient’s perspective needs to be explored further as it may differ considerably from the physician’s perspective. Key recommendations from the working group to tackle unmet needs included reducing time to diagnosis, increasing patient and physician disease awareness, focusing on patients’ priorities for treatment goals, and improving patient–physician communication. By addressing these key action points moving forward, the hope is that outcomes will continue to improve for patients with PsA and AxSpA.

show abstract

“…Moreover, the impact of disease activity on fatigue in inflammatory diseases remains a controversial issue. Some investigators claim that fatigue increases with high disease activity, while others have not confirmed such a relationship . This issue has not yet been thoroughly studied in patients with psoriasis.…”

mentioning

confidence: 99%

Fatigue in psoriasis: a controlled study

et al. 2017

View full text Add to dashboard Cite

show abstract

Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries

Cited by 50 publications

References 18 publications

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Fatigue in psoriasis: a controlled study

Contact Info

Product

Resources

About